Pilaralisib

Pilaralisib Uses, Dosage, Side Effects, Food Interaction and all others data.

Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

In preclinical studies, Pilaralisib slowed tumor growth or caused tumor shrinkage in multiple preclinical cancer models, including breast, lung, ovarian, and prostate cancers, and gliomas. Pilaralisib has also been shown to enhance the anti- tumor effects of several chemotherapeutic agents and an inhibitor of epidermal growth factor receptor (EGFR) in preclinical cancer models.

Trade Name Pilaralisib
Generic Pilaralisib
Pilaralisib Other Names Pilaralisib
Type
Formula C25H25ClN6O4S
Weight Average: 541.02
Monoisotopic: 540.1346522
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Pilaralisib
Pilaralisib

How Pilaralisib works

Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.

Elimination Route

Orally available

Innovators Monograph

You find simplified version here Pilaralisib

*** Taking medicines without doctor's advice can cause long-term problems.
Share